Physician profile
Devinder Kumar
NPI 1548251390
$11,154.64
in general payments reported to CMS, 2019-2025
37 companies · $659 in 2025
The $659 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,003 · 2020: $1,390 · 2021: $1,491 · 2022: $1,413 · 2023: $1,363 · 2024: $1,835 · 2025: $659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,857.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,087.12 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,104.37 | 2019-2024 | Austedo Xr, Austedo, Ajovy |
| Astrazeneca Pharmaceuticals Lp | $976.96 | 2019-2024 | Airsupra, Andexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $773.04 | 2019-2024 | Relistor |
| Amgen INC. | $693.48 | 2019-2023 | Evenity, Prolia |
| Lilly USA, LLC | $555.93 | 2019-2025 | Mounjaro, Emgality, Reyvow |
| Daiichi Sankyo INC. | $418.34 | 2019 | |
| Pfizer INC. | $393.50 | 2019-2025 | |
| Radius Health, INC. | $348.99 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $333.34 | 2019-2020 | |
| Horizon Therapeutics Plc | $306.83 | 2019-2021 | |
| Impel Pharmaceuticals INC. | $289.55 | 2023 | Trudhesa |
| Forte Bio-Pharma LLC | $270.04 | 2019-2021 | |
| Novo Nordisk INC | $250.00 | 2019-2024 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $242.03 | 2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $242.02 | 2021 | |
| Arbor Pharmaceuticals, INC. | $236.82 | 2020-2021 | |
| Redhill Biopharma INC. | $210.82 | 2020-2023 | Movantik, Aemcolo, Talicia |
| Allergan, INC. | $183.68 | 2020 | |
| Ferring Pharmaceuticals INC. | $140.98 | 2024 | Rebyota |
| Fidia Pharma USA INC. | $136.49 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $128.16 | 2024 | Voquezna |
| Glaxosmithkline, LLC. | $124.99 | 2024 | Arexvy |
| Gilead Sciences, INC. | $124.99 | 2019 | |
| Zyla Life Sciences, INC. | $114.87 | 2019-2020 | |
| Si-Bone, INC. | $51.36 | 2019 | |
| Lundbeck LLC | $50.97 | 2021-2024 | Vyepti |
| Assertio Therapeutics, INC. | $50.00 | 2019-2020 | |
| Virtus Pharmaceuticals LLC | $49.69 | 2023-2024 | Levorphanol Tartrate |
| Depuy Synthes Sales INC. | $45.77 | 2023 | Orthovisc |
| Novartis Pharmaceuticals Corporation | $40.45 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $38.00 | 2022 | |
| Collegium Pharmaceutical, INC. | $35.88 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $32.94 | 2019 | |
| Indivior INC. | $26.55 | 2019 | |
| Almatica Pharma LLC | $24.82 | 2023 | Gralise |
| Spr Therapeutics, INC | $20.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devinder Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.